Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
about
Can lipoprotein-associated phospholipase A2 be used as a predictor of long-term outcome in patients with acute coronary syndrome?Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionPhospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizationsThe Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of AtherosclerosisAnti-inflammatory therapies for cardiovascular diseaseRandomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.Biomechanics and inflammation in atherosclerotic plaque erosion and plaque rupture: implications for cardiovascular events in womenEx vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDSMitochondrial Reactive Oxygen Species Mediate Lysophosphatidylcholine-Induced Endothelial Cell Activation.Cytosolic phospholipase A(2)α protects against ischemia/reperfusion injury in the heart.Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.New lipid-lowering drugs: an update.The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis.Immune-mediated mechanisms of atherosclerosis and implications for the clinic.After FRANCIS: next steps in the clinical evaluation of varespladib methyl.Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade.Atherosclerosis Is an Inflammatory Disease which Lacks a Common Anti-inflammatory Therapy: How Human Genetics Can Help to This Issue. A Narrative Review.Research Progress on the Relationship between Atherosclerosis and Inflammation
P2860
Q26853640-D3C2BCEF-5DA2-4F0B-B41D-8E08AF32646AQ26997377-FFD623B7-7617-4ADA-A0A4-EEFC3721696FQ28286551-E6881B8E-6179-49BE-B51A-FE75AF0F21BDQ33838927-AA9E018E-B71D-4C5B-B3E3-4B00C4F58CE5Q34137872-337E151A-8143-44F8-83F1-90B8168E3C33Q34150154-0BBA42E2-F9B4-4B36-A460-8D092A764EA2Q34445799-300EBDB3-C11B-432F-B975-C5059F060B7BQ34447842-B65C5359-0C9B-458A-A529-A368E3971237Q34524163-144B538D-2A01-45EB-9723-BF3C7F0AC619Q35205874-C9C19497-64C3-4A59-A0B3-E1B03DC8B384Q35592510-94674B84-157D-4B5A-B17B-0BF6BBA8145FQ37303915-38668BA5-2832-4209-9617-7AEE1A12A661Q37984782-079D07BA-55AF-4F61-880D-5F2C310B0436Q38593722-514E0A6D-BA77-4760-9C21-E96B73B2A947Q38707328-4E9C634E-B7C6-4690-B53B-02F59642CB0EQ38786058-9182A21A-EEEA-475F-AC40-C00C1E692B98Q38851472-470823CD-B5F3-4ABD-B3B1-D2B27437BE79Q39803214-3A22A634-61B4-4696-B647-FBDDB505A65BQ46218671-07E2B9AF-E040-4C39-B827-DCFFC7344E6CQ50318400-99F58209-3D46-4EBC-9FE7-2BA074A20F2DQ58710440-3EA1AE55-6986-4EC2-8E90-5AEF96466FA9
P2860
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effects of varespladib methyl ...... te coronary syndrome patients.
@ast
Effects of varespladib methyl ...... te coronary syndrome patients.
@en
Effects of varespladib methyl ...... te coronary syndrome patients.
@nl
type
label
Effects of varespladib methyl ...... te coronary syndrome patients.
@ast
Effects of varespladib methyl ...... te coronary syndrome patients.
@en
Effects of varespladib methyl ...... te coronary syndrome patients.
@nl
prefLabel
Effects of varespladib methyl ...... te coronary syndrome patients.
@ast
Effects of varespladib methyl ...... te coronary syndrome patients.
@en
Effects of varespladib methyl ...... te coronary syndrome patients.
@nl
P2093
P1476
Effects of varespladib methyl ...... te coronary syndrome patients.
@en
P2093
Colin Hislop
David Waters
Michael Elliott
Michael Goulder
Robert S Rosenson
Yuri Stasiv
P304
P356
10.1016/J.JACC.2010.06.015
P407
P577
2010-09-01T00:00:00Z